Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 Hours

Diabetes Technology and Therapeutics

Volumn 16, Issue 3, 2014, Pages 131-136

  Van Bon, Arianne C ^a,c   Luijf, Yoeri M ^a   Koebrugge, Rob ^b   Koops, Robin ^b   Hoekstra, Joost B L ^a   Devries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Inreda Diabetic BV   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; RECOMBINANT GLUCAGON; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLUCOSE SENSOR; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; PATIENT CARE; PORTABLE BIHORMONAL CLOSED LOOP SYSTEM; PRIORITY JOURNAL; TELEMONITORING; YOUNG ADULT; ALGORITHM; AMBULATORY MONITORING; BLOOD; CALIBRATION; DIABETES MELLITUS, TYPE 1; EVALUATION STUDY; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; INSULIN INFUSION; METABOLISM; METRONOMIC DRUG ADMINISTRATION; TELEMEDICINE;

ADMINISTRATION, METRONOMIC; ADULT; ALGORITHMS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CALIBRATION; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDIES; FEMALE; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; TELEMEDICINE;

EID: 84896888057     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0166     Document Type: Article

References (16)

1. Breton M, Farret A, Bruttomesso D, Anderson S, Magni L, Patek S, Dalla Man C, Place J, Demartini S, Del Favero S, Toffanin C, Hughes-Karvetski C, Dassau E, Zisser H, Doyle FJ 3rd, De Nicolao G, Avogaro A, Cobelli C, Renard E, Kovatchev B; International Artificial Pancreas Study Group: Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230-2237.
2. Clarke WL, Anderson S, Breton M, Patek S, Kashmer L, Kovatchev B: Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol 2009;3:1031-1038.
3. Hovorka R: Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011;7:385-395.
4. Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, Clarke W, Bruttomesso D, Maran A, Costa S, Avogaro A, Dalla Man C, Facchinetti A, Magni L, De Nicoloa G, Place J, Farret A: Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010;4:1374-1381.
5. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De Palma A, Wilkinska ME, Acerini CL, Dunger DB: Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375:743-751.
6. Renard E; AP@home consortium: Time in hypoglycemia in patients with type 1 diabetes is dramatically reduced when insulin infusion is driven by two closed-loop algorithms in a randomised clinical trial [abstract]. Diabetologia 2012;55(Suppl 1):S86.
7. Philip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, Biester T, Stefanija MA, Muller I, Nimri R, Danne T: Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824-833.
8. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER: Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012;35:2148-2155.
9. Castle JR, Engle JM, El YJ, Massoud RG, Yuen KC, Kagan R, Ward WK: Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287.
10. Haidar A, Lequalt L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B, Rabasa-Lhoret R: Glucose-responsive insulin and glucagon delivery (dualhormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013;185: 297-305.
11. van Bon AC, Hermanides J, Koops R, Hoekstra JB, Devries JH: Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study. J Diabetes Sci Technol 2010;4:923-928.
12. van Bon AC, Jonker LD, Koebrugge R, Koops R, Hoekstra JB, Devries JH: Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions. J Diabetes Sci Technol 2012;6:1114-1122.
13. Gold AE, MacLeod KM, Frier BM: Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703.
14. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W: Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;18:517-522.
15. Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R: Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci 1999;88:991-995.
16. Devries JH, Snoek FJ, Kostense PJ, Heine RJ: Improved glycaemic control in type 1 diabetes patients following participation per se in a clinical trial-mechanisms and implications. Diabetes Metab Res Rev 2003;19:357-362.